Orphai Therapeutics

02/15/2024

OrphAI Therapeutics has been granted Orphan Drug Designation by the EU for AIT-101, aimed at treating amyotrophic lateral sclerosis (ALS). Following its US FDA approval, this marks a significant step toward battling this neurodegenerative disease.

GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel...

09/28/2023

Exciting News! AI Therapeutics has rebranded to OrphAI Therapeutics Inc. as we further our commitment to treating rare diseases. Our new name captures our evolution & dedication to those in need. Check out our brand new website: OrphAI-Therapeutics.com

https://www.globenewswire.com/news-release/2023/09/28/2751457/0/en/AI-Therapeutics-Announces-Name-Change-to-OrphAI-Therapeutics.html

GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for...

04/05/2023

AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)

Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active...

04/25/2022

AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)

Innovative, first-in-class compound for the treatment of rare pediatric cancers expands AI Therapeutics product pipeline

Read More:

Innovative, first-in-class compound for the treatment of rare pediatric cancers expands AI Therapeutics product pipeline...

02/16/2022

AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer

Former Healthcare Investor Takes Helm at Clinical-Stage Biopharmaceutical Company to Advance Life-Saving Treatments for Rare Diseases...

01/13/2022

AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS

Promising New Approach for a Fatal Neurological Disorder...

05/04/2021

U.S. Senator Chris Murphy announced AI Therapeutics, based in Guilford, has been named “Innovator of the Month.”

HARTFORD—U.S. Senator Chris Murphy (D-Conn.) announced AI Therapeutics, based in Guilford, has been...

05/02/2021

Thank you Senator Chris Murphy for naming AI Therapeutics "Innovator of the Month"

04/30/2021

Murphy Highlights Guilford Innovator AI Therapeutics as "Murphy's Innovator of the Month"

“We are honored to be recognized by Senator Murphy as Innovator of the Month. We remain dedicated to our mission of bringing life-saving drugs to patients with rare diseases with our pipeline."

HARTFORD—U.S. Senator Chris Murphy (D-Conn.) announced AI Therapeutics, based in Guilford, has been...

11/13/2020

Our aim is to accelerate drug development and increase clinical success by matching drugs to the right patients.

We are continually teaching the Guardian Angel™ algorithm how to match drugs to patients.

11/10/2020

"AI Therapeutics, a company founded by Connecticut serial entrepreneur Jonathan Rothberg, says it uses to mine clinical, genomic and literature-based data to identify drug candidates that have already demonstrated evidence of clinical safety in patients."

New Haven’s BioXcel Therapeutics has been a company for only three years, yet it’s on track to have its first commercial drug by the end of 2021 — a dissolving film that’s similar to a mouthwash strip and can quickly calm agitated patients.